Proteomic insights into paediatric cancer: Unravelling molecular signatures and therapeutic opportunities
Open Access
- 31 March 2024
- journal article
- review article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 71 (6) , e30980
Abstract
Survival rates in some paediatric cancers have improved greatly over recent decades, in part due to the identification of diagnostic, prognostic and predictive molecular signatures, and the development of risk‐directed therapies. However, other paediatric cancers have proved difficult to treat, and there is an urgent need to identify novel biomarkers that reveal therapeutic opportunities. The proteome is the total set of expressed proteins present in a cell or tissue at a point in time, and is vastly more dynamic than the genome. Proteomics holds significant promise for cancer research, as proteins are ultimately responsible for cellular phenotype and are the target of most anticancer drugs. Here, we review the discoveries, opportunities and challenges of proteomic analyses in paediatric cancer, with a focus on mass spectrometry (MS)‐based approaches. Accelerating incorporation of proteomics into paediatric precision medicine has the potential to improve survival and quality of life for children with cancer.Keywords
Funding Information
- Australian Cancer Research Foundation
- NSW Ministry of Health (CMP‐01)
- University of Sydney
- Cancer Council NSW (IG 18‐01)
- Ian Potter Foundation
- National Health and Medical Research Council (GNT1170739, GNT2000855)
- National Breast Cancer Foundation (IIRS‐18‐164)
- Cancer Institute NSW (2017/TPG001, REG171150, 2021/CBG0002)
This publication has 103 references indexed in Scilit:
- Children's Oncology Group's 2023 blueprint for research: Central nervous system tumorsPediatric Blood & Cancer, 2023
- Children's Oncology Group blueprint for research: Acute lymphoblastic leukemiaPediatric Blood & Cancer, 2023
- Late effects and treatment related morbidity associated with treatment of neuroblastoma patients in a tertiary paediatric centreCancer Reports, 2022
- Inflammatory biomarkers after an exercise intervention in childhood acute lymphoblastic leukemia survivorseJHaem, 2022
- Opportunities for pharmacoproteomics in biomarker discoveryProteomics, 2022
- An update on rhabdomyosarcoma risk stratification and the rationale for current and future Children's Oncology Group clinical trialsPediatric Blood & Cancer, 2022
- A critical comparison of three MS‐based approaches for quantitative proteomics analysisJournal of Mass Spectrometry, 2020
- Kinobeads: A Chemical Proteomic Approach for Kinase Inhibitor Selectivity Profiling and Target Discovery2019
- Addressing the Challenges of High‐Throughput Cancer Tissue Proteomics for Clinical Application: ProCanProteomics, 2019
- The utility of alpha‐fetoprotein screening in Beckwith–Wiedemann syndromeAmerican Journal of Medical Genetics Part A, 2017